Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Zheng-Yi Zhou, Shawn Sun, Pooja Chopra, Yichen Zhong, Todor Totev & James Signorovitch. (2015) Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder. Journal of Medical Economics 18:11, pages 919-929.
Read now
Read now
Andrew P. Yu, Jipan Xie, Arielle Bensimon, Kejal Parikh, Eric Q. Wu, Rym Ben-Hamadi, Steven Blum & M. Haim Erder. (2010) Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study. Journal of Medical Economics 13:4, pages 599-609.
Read now
Read now
Alan G. Wade, Delphine Saragoussi, Nicolas Despiégel, Clément François, Florent Guelfucci & Mondher Toumi. (2010) Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK. Current Medical Research and Opinion 26:5, pages 1161-1170.
Read now
Read now
Eric Q. Wu, Paul E. Greenberg, Elaine Yang, Andrew P. Yu, Rym Ben-Hamadi & M. Haim Erder. (2009) Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs. Journal of Medical Economics 12:2, pages 124-135.
Read now
Read now
Feng Xie, Nicolas Despiegel, Natalya Danchenko & Karina Hansen. (2009) Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. International Journal of Psychiatry in Clinical Practice 13:1, pages 59-69.
Read now
Read now
Cyril Höschl & Jaromír Švestka. (2008) Escitalopram for the treatment of major depression and anxiety disorders. Expert Review of Neurotherapeutics 8:4, pages 537-552.
Read now
Read now
Raymond W Lam & Lieven Annemans. (2007) Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. Expert Review of Pharmacoeconomics & Outcomes Research 7:6, pages 559-576.
Read now
Read now
Christophe Lançon, Patrice Verpillat, Lieven Annemans, Nicolas Despiegel & Clément François. (2007) Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram. International Journal of Psychiatry in Clinical Practice 11:1, pages 44-52.
Read now
Read now
Michael E Thase. (2006) Treatment of anxiety disorders with venlafaxine XR. Expert Review of Neurotherapeutics 6:3, pages 269-282.
Read now
Read now
Michael E Thase. (2006) Managing depressive and anxiety disorders with escitalopram. Expert Opinion on Pharmacotherapy 7:4, pages 429-440.
Read now
Read now
Articles from other publishers (13)
Xiaoliang Wang, Yimin Fan, Guanjun Li & Huafang Li. (2021) The efficacy of escitalopram in major depressive disorder: a multicenter randomized, placebo-controlled double-blind study. International Clinical Psychopharmacology 36:3, pages 133-139.
Crossref
Crossref
Lieven Annemans, Mélanie Brignone, Sylvain Druais, Ann De Pauw, Aline Gauthier & Koen Demyttenaere. (2014) Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium. PharmacoEconomics 32:5, pages 479-493.
Crossref
Crossref
Mark J.C. Nuijten, Mélanie Brignone, Florence Marteau, Johan A. den Boer & Erik Hoencamp. (2012) Cost-Effectiveness of Escitalopram in Major Depressive Disorder in the Dutch Health Care Setting. Clinical Therapeutics 34:6, pages 1364-1378.
Crossref
Crossref
Göran Nordström, Natalya Danchenko, Nicolas Despiegel & Florence Marteau. (2012) Cost-Effectiveness Evaluation in Sweden of Escitalopram Compared with Venlafaxine Extended-Release as First-Line Treatment in Major Depressive Disorder. Value in Health 15:2, pages 231-239.
Crossref
Crossref
H.-J. Möller, I. Bitter, J. Bobes, K. Fountoulakis, C. Höschl & S. Kasper. (2020) Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. European Psychiatry 27:2, pages 114-128.
Crossref
Crossref
Marieke Krol, Jocé Papenburg, Marc Koopmanschap & Werner Brouwer. (2012) Do Productivity Costs Matter?. PharmacoEconomics 29:7, pages 601-619.
Crossref
Crossref
Jian-Jun Ou, Guang-Lei Xun, Ren-Rong Wu, Le-Hua Li, Mao-Sheng Fang, Hong-Geng Zhang, Shi-Ping Xie, Jian-Guo Shi, Bo Du, Xue-Qin Yuan & Jing-Ping Zhao. (2010) Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology 213:2-3, pages 639-646.
Crossref
Crossref
Brian Leonard & David Taylor. (2010) Review: Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression. Journal of Psychopharmacology 24:8, pages 1143-1152.
Crossref
Crossref
Dietmar Winkler, Edda Pjrek, Ulrike Moser & Siegfried Kasper. (2007) Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria. Human Psychopharmacology: Clinical and Experimental 22:4, pages 245-251.
Crossref
Crossref
P. M. Llorca & J.-L. Fernandez. (2007) Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. International Journal of Clinical Practice 61:4, pages 702-710.
Crossref
Crossref
Hamid Sadri & Nicole Mittmann. (2016) A Qualitative Review of Recent Economic Evaluations of Escitalopram. Journal of Pharmacy Technology 23:1, pages 35-40.
Crossref
Crossref
María Velasco, Luis Salvador, Carmelo Juárez & Fernando Antoñanzas. (2013) Análisis de coste-efectividad de escitalopram comparado con citalopram en el tratamiento de pacientes con depresión mayor grave. PharmacoEconomics Spanish Research Articles 3:2, pages 63-73.
Crossref
Crossref
David Murdoch & Susan J Keam. (2005) Escitalopram. Drugs 65:16, pages 2379-2404.
Crossref
Crossref